에스토니아 - 에스토니아어 - Ravimiamet

fresenius kabi deutschland gmbh - kaaliumkloriid+naatriumkloriid - infusioonilahus - 1,5mg+9mg 1ml 500ml 10tk

에스토니아 - 에스토니아어 - Ravimiamet

fresenius kabi deutschland gmbh - kaaliumkloriid+naatriumkloriid - infusioonilahus - 3mg+9mg 1ml 1000ml 10tk

에스토니아 - 에스토니아어 - Ravimiamet

fresenius kabi deutschland gmbh - kaaliumkloriid+glükoos - infusioonilahus - 3mg+50mg 1ml 500ml 10tk; 3mg+50mg 1ml 1000ml 10tk

에스토니아 - 에스토니아어 - Ravimiamet

fresenius kabi polska sp. z o.o. - elektrolüüdid+süsivesikud - infusioonilahus - 100ml 40tk; 250ml 20tk; 500ml 10tk

에스토니아 - 에스토니아어 - Ravimiamet

laboratorios basi industria farmaceutica s.a. - paratsetamool - infusioonilahus - 10mg 1ml 100ml 50tk

유럽 연합 - 에스토니아어 - EMA (European Medicines Agency)

accord healthcare s.l.u. - sildenafiili tsitraat - hüpertensioon, kopsuvähk - uroloogilised ravimid - adultstreatment täiskasvanud patsientidel pulmonaalse arteriaalse hüpertensiooni klassifitseeritud kes funktsionaalse klassi ii ja iii lisa, et parandada kasutada mahutavus. efektiivsus on näidustatud sidekoehaigusega seotud primaarse pulmonaalse hüpertensiooniga ja kopsu hüpertensiooniga. lastel populationtreatment pediaatriliste patsientide vanuses 1 aasta kuni 17 aastat vana pulmonaalse arteriaalse hüpertensiooni. treenimisvõime või kopsu hemodünaamika paranemise efektiivsust on näidatud kaasasündinud südamehaigusega seotud primaarse pulmonaalse hüpertensiooniga ja kopsu hüpertensiooniga.

유럽 연합 - 에스토니아어 - EMA (European Medicines Agency)

alexion europe sas - eculizumab - hemoglobinuuria, paroksüsmaalne - immunosupressandid - soliris on näidatud täiskasvanute ja laste raviks:paroxysmal öise haemoglobinuria (pnh). tõendeid kliinilise kasu on näidanud patsientidel haemolysis kliiniliste sümptomite(s) soovituslik kõrge haiguse aktiivsusega, sõltumata sellest, vereülekande ajalugu (vt lõik 5. ebatüüpiline hemolüütilis-ureemilise sündroomi (ahus). soliris on näidustatud täiskasvanute raviks:tulekindlad generaliseerunud myasthenia gravis (gmg) patsientidel, kes on anti-atsetüülkoliin retseptori (achr) antikeha-positiivsete (vt lõik 5. neuromyelitis optica spectrum disorder (nmosd) patsientidel, kes on anti-aquaporin-4 (aqp4) antikeha-positiivsete koos relapsing haiguse kulg.

유럽 연합 - 에스토니아어 - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinuuria, paroksüsmaalne - selektiivsed immunosupressandid - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

에스토니아 - 에스토니아어 - Ravimiamet

mylan s.a.s. - vinorelbiin - infusioonilahuse kontsentraat - 10mg 1ml 10mg 1tk; 10mg 1ml 50mg 1tk

에스토니아 - 에스토니아어 - Ravimiamet

krka d.d. novo mesto - vardenafiil - õhukese polümeerikattega tablett - 5mg 2tk; 5mg 4tk; 5mg 20tk